<DOC>
	<DOC>NCT00749944</DOC>
	<brief_summary>Study objective is to compare neuropsychiatric adverse events in subjects treated with varenicline or placebo in a controlled setting where both groups are experiencing nicotine withdrawal.</brief_summary>
	<brief_title>Assessing Neuropsychiatric Symptoms Including Depression, Anxiety, Irritability, and Suicidal Thoughts or Behavior in Subjects Quitting Smoking on Varenicline Tartrate or Placebo</brief_title>
	<detailed_description />
	<mesh_term>Varenicline</mesh_term>
	<criteria>smokers who smoke &gt;10 cigarettes/day and who have at least a moderate level of addiction as measured by the Fagerstrom Test for Nicotine Dependence (score &gt;5) Any neuropsychiatric disease including depression, history of suicidal thoughts or behavior, bipolar disorder. Any unstable medical condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>nicotine withdrawal, smoking cessation, varenicline</keyword>
</DOC>